Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EchiTAb+ ICP
- Development stage
- Preclinical
- Lead developer
- Instituto Clodomiro Picado
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EchiTAb+ ICP is a lyophilized polyvalent antivenom developed by the Instituto Clodomiro Picado (ICP) for the treatment of snakebite envenomation caused by medically important sub-Saharan African snake species. It is a biologic product consisting of horse-derived polyclonal antibodies (IgG) produced by immunizing horses with a mixture of venoms from seven key species: *Echis ocellatus* (West African carpet viper), *Bitis arietans* (puff adder), *Naja nigricollis* (black-necked spitting cobra), *Naja mossambica* (Mozambique spitting cobra), *Naja annulifera* (snouted cobra), *Dendroaspis polylepis* (black mamba), and *Hemachatus haemachatus* (rinkhals). The antivenom works by binding to and neutralizing a wide array of venom toxins, including metalloproteinases, phospholipases A2, and both post-synaptic and pre-synaptic neurotoxins, thereby preventing their interaction with physiological targets and mitigating the hemotoxic and neurotoxic effects of envenomation.
- Brand names
- EchiTAb+ ICP
- Other names
- EchiTAb-Plus-ICP
02
Targets
DpV (Black mamba venom toxins)SVMP (Snake venom metalloproteinase)Echis ocellatus venom toxinsNaja spitting cobra venom toxins
Beyond the preview
Go deeper on EchiTAb+ ICP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EchiTAb+ ICP.